SIGA TECHNOLOGIES INC (SIGA)
Health Care · biotechnology / pharmaceutical defense countermeasures · NASDAQ
SIGA Technologies is a pharmaceutical company providing critical antiviral countermeasures, primarily TPOXX, to protect against smallpox and other orthopoxvirus threats.
What SIGA TECHNOLOGIES INC does
SIGA Technologies is a commercial-stage pharmaceutical company focused on the development and commercialization of health security countermeasures. Its primary product is TPOXX (tecovirimat), an antiviral medication approved for the treatment of smallpox, which it supplies to the U.S. government and various international government agencies in both oral and intravenous formulations.
Recent developments
On May 29, 2026, the European Commission adopted an opinion to remove the mpox indication for Tecovirimat-SIGA. In Q2 2026, the company delivered $24 million of IV TPOXX to the U.S. Strategic National Stockpile, completing the last procurement order under the 19C BARDA contract. The company is currently targeting a Supplemental NDA submission for a smallpox post-exposure prophylaxis (PEP) indication in the first half of 2027.
From SIGA TECHNOLOGIES INC's filing of 2026-08-06.
Themes: biodefense, infectious diseases, orthopoxvirus treatment, government procurement, antivirals
Fundamentals
- Price$3.15 as of 2026-10-20 close
- Market cap$226M as of 2026-07-24 (share count; price 2026-10-20)
- 1-year return-62.9% 2025-10-20 close $8.48 → 2026-10-20 close $3.15
- P/En/a negative earnings
- Net margin+24.6% FY2025, SEC XBRL
- ROE+11.7% FY2025, SEC XBRL
- ROICn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)-31.8% FY2025, SEC XBRL
- Revenue CAGR (3y)-5.1% SEC XBRL
- Beta0.69 as of 2026-09-02
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
Dividend: at least 4 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How SIGA compares in its sector
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-02
- operating margintop 10% 417 covered Health Care peers, as of 2026-09-02
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage (FY2025)
Exceeded at least one reported measure. In FY2025, SIGA's dividend exceeded at least one reported measure of what it earned or generated (earnings payout 185%, operating-cash-flow payout 99%). A payout above 100% in one year is not necessarily unsustainable, but it is not fully covered by that measure.
- Earnings payout185% dividends / net income
- Operating-cash-flow payout99% dividends / operating cash flow — capital spending was not reported, so this does not subtract it
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $41M | $14M | $12M | $0.17 | $15M† |
| Q1 FY2026 2026-03-31 | $6M | -$5M | -$3M | -$0.05 | -$9M |
| Q4 FY2025 2025-12-31 | $4M† | -$9M† | -$5M† | -$0.08† | -$17M† |
| Q3 FY2025 2025-09-30 | $3M | -$10M | -$6M | -$0.09 | -$10M† |
| Q2 FY2025 2025-06-30 | $81M | $46M | $35M | $0.49 | $63M† |
| Q1 FY2025 2025-03-31 | $7M | -$2M | -$408223 | -$0.01 | $7M |
| Q4 FY2024 2024-12-31 | $81M† | $57M† | $46M† | $0.63† | $56M† |
| Q3 FY2024 2024-09-30 | $10M | $542087 | $1M | $0.02 | -$7M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$118M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How SIGA TECHNOLOGIES INC looks technically
SIGA TECHNOLOGIES INC (SIGA) is trading 30.9% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 203 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 46, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 9 trading days ago (its momentum flipped negative). It made a new 20-day high about 12 trading days ago. It is 63.2% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 30.9% below its 200-day average, the long-term trend line — a long-term downtrend | -30.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.15 | $3.15 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.56 | $4.56 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 3.68. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 203 trading days ago — a "death cross", a bearish long-term signal | 203 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend) | 16.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 46, neither overbought (above 70) nor oversold (below 30) | 45.8 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($3.04 to $3.68) — its "stochastic" reading is 17 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 17.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 9 trading days ago (its momentum flipped negative) | 9 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $8.55 | $8.55 |
|---|---|---|
| From the 52-week high | it is 63.2% below its 52-week high (its highest price of the past year) | -63.2% |
| Above the 52-week low | it is 11.3% above its 52-week low (its lowest price of the past year) | +11.3% |
| Below the 52-week high | it is 63.2% below its highest point of the past year | 63.2% |
| Since a 20-day breakout | it made a new 20-day high about 12 trading days ago | 12 sessions |
| Since a 55-day breakout | it made a new 55-day low about 49 trading days ago | 49 sessions |
| All-time high | its highest closing price on record is $26.99 (set on 2022-08-15) | $26.99 |
| Given back of the 52-week move | over the past year its closes ranged ($2.87 to $8.48), and it has recovered only a small part of its fall from last year’s high — 5% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $6.34 to $6.52. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 5.0% |
| From the all-time high | it is 88.3% below its all-time high | -88.3% |
| Nearest price level | it is trading 7.3% above a support level at $2.92 — a price it turned at twice since 2026-08-27, most recently on 2026-09-16. Since 2024-10-21 it has 1 such level below the current price and 15 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -7.3% |
| All-time low | its lowest closing price on record is $0.2 (set on 2015-12-24) | $0.2 |
| Above the all-time low | it is 1475.0% above its all-time low | +1,475% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 71% of it) | 29th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1384 between its high and its low — about 4.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1384 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.02 and $3.52 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.02 – $3.27 – $3.52 |
| Typical daily range (% of price) | its price moves about 4.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.4% |
| Stretch from the 200-day average | it is trading 10.2 daily ranges below its 200-day average price (30.9% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 10.2 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.52× |
|---|
Analyst
2
| Change in the average price target | not available for this company yet | n/a |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a hammer | 2 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 2 sessions ago |
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
Price gaps
1
| Gap at the open | it opened on 2026-10-20 0.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.3% |
|---|
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 0.6 percentage points (the stock gained 0.3% while the market gained 1.0%) | -0.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 13.1 percentage points (the stock lost 9.5% while the market gained 3.6%) | -13.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 39.6 percentage points (the stock lost 31.1% while the market gained 8.5%) | -39.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 77.4 percentage points (the stock lost 62.9% while the market gained 14.6%) | -77.4% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 8.7% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 27% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $4.32 — a volume-weighted average of daily closes over 197 sessions, not a true tick-by-tick VWAP. | -27.1% |
|---|
Price levels it has turned at before
SIGA last closed at $3.15 on 2026-10-20. Since 2024-10-21 it has turned at 1 price below its last close and 15 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.92 | Support | 7.3% below the last close | turned there twice · 2026-08-27 to 2026-09-16 |
| $4.42 | Resistance | 40.2% above the last close | turned there twice · 2026-04-21 to 2026-06-22 |
| $4.80 | Resistance | 52.5% above the last close | turned there three times · 2026-03-18 to 2026-05-22 |
| $4.93 | Resistance | 56.7% above the last close | turned there twice · 2025-04-04 to 2026-05-11 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $3.68.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 11 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · trendless / choppy (low ADX) · lagging the market · Printed a doji candle | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Key risks (from latest filing)
["High dependence on procurement contracts with the U.S. government, specifically BARDA.","Uncertainty surrounding regulatory approval and maintenance of marketing authorizations, particularly with respect to indications like mpox.","Concentration of revenue in a single product, TPOXX."]
What changed in the latest 10-Q
AI-assisted comparison of SIGA's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 2025 Form 10-K filed March 10, 2026 (newer filing)
- Specification that oral TPOXX® formulation is 'the oral formulation of TPOXX®' (newer filing)
- Details on CHMP's March 27, 2026 opinion confirming positive benefit-risk balance for smallpox, cowpox, and vaccinia complications, recommending removal of mpox indication (newer filing)
- Reference to April 2026 MHRA request to align UK label with referral procedure outcome (newer filing)
- Addition of 'and uncertainty' in macroeconomic discussion regarding tariffs and trade policies (newer filing)
- Addition of 'or other trading restrictions' in IV TPOXX® tariff discussion (newer filing)
- Addition of 'support for manufacturing activities' to BARDA contract funding activities list (newer filing)
- Update of BARDA contract status date from September 30, 2025 to March 31, 2026 (newer filing)
- Removed:
- Phrase 'most recently, in December 2024' regarding PMDA approval (older filing, removed in newer)
- Reference to 2024 Form 10-K filed March 11, 2025 (older filing)
- Reference to Form 10-Q for period ended June 30, 2025 in Risk Factors (older filing)
- Statement that 'EMA will now review' and reference to ongoing MHRA reassessment process (older filing)
- Phrase 'in 2026' for Supplemental NDA submission timing, changed to 'within the next twelve months' (older filing)
- Reworded:
- Supplemental NDA submission timing changed from 'in 2026' (older) to 'within the next twelve months' (newer)
- CHMP referral procedure status changed from prospective review ('EMA will now review') to completed review with issued opinion (newer filing)
- Macroeconomic language expanded from 'changes to tariffs and trade policies' (older) to 'changes to and uncertainty regarding tariffs and trade policies' (newer)
- IV TPOXX® tariff impact language expanded from 'tariff activity' (older) to 'tariff activity or other trading restrictions' (newer)
- BARDA contract funding description now includes 'support for manufacturing activities' as separate item from 'procurement activities' (newer)
- Notes:
- Comparison reflects completion of EMA referral procedure and CHMP opinion between the two filing dates
- Document appears truncated at end of BARDA contract section in both versions, limiting full comparison of that section
- Timing references reflect different quarterly periods (March 31, 2026 vs September 30, 2025)
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for SIGA — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding SIGA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 6,907,421
- Reported value $25,143,012
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about SIGA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
SIGA had 3,600,907 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
SIGA had 5.01% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.21 days to cover at the same settlement.
- Reported short interest (shares) 3,600,907
- Short interest (% of shares outstanding) 5.01%
- Prior settlement (shares) 3,729,992
- Reported change -3.46%
- Days to cover (reported) 5.21
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Emergent BioSolutions (EBS)
- Bavarian Nordic (BVNRY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SIGA vs…
Frequently asked questions
What does SIGA TECHNOLOGIES INC (SIGA) do?
SIGA Technologies is a commercial-stage pharmaceutical company focused on the development and commercialization of health security countermeasures. Its primary product is TPOXX (tecovirimat), an antiviral medication approved for the treatment of smallpox, which it supplies to the U.S. government and various international government agencies in both oral and intravenous formulations.
What sector is SIGA TECHNOLOGIES INC (SIGA) in?
SIGA TECHNOLOGIES INC (SIGA) is classified in the Health Care sector. Its industry is biotechnology / pharmaceutical defense countermeasures. It trades on NASDAQ.
Does SIGA pay a dividend?
Yes — SIGA TECHNOLOGIES INC (SIGA) pays a dividend, with at least 4 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-09-02). Informational only — not financial advice.
Who are SIGA TECHNOLOGIES INC's (SIGA) competitors?
Notable peers of SIGA TECHNOLOGIES INC (SIGA) include Emergent BioSolutions and Bavarian Nordic. This peer set is informational only — not financial advice.
Is SIGA TECHNOLOGIES INC (SIGA) overbought or oversold right now?
SIGA TECHNOLOGIES INC (SIGA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 46, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SIGA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.